Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effect of KATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Headache provocation by nitric oxide in men who have never experienced a headache

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Prevalence of neck pain in migraine: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  1. Effect of KATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences

    Research output: Contribution to journalReviewResearchpeer-review

  3. One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Involvement of adenosine signaling pathway in migraine pathophysiology: A systematic review of clinical studies

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: This post hoc subgroup analysis evaluated the efficacy and safety of eptinezumab for migraine prevention in patients with migraine and self-reported aura.

METHODS: PROMISE-1 (NCT02559895; episodic migraine) and PROMISE-2 (NCT02974153; chronic migraine) were randomized, double-blind, placebo-controlled trials that evaluated eptinezumab for migraine prevention. In both studies, the primary outcome was the mean change from baseline in monthly migraine days over Weeks 1-12. Patients in this analysis included those who self-reported migraine with aura at screening.

RESULTS: Of patients with episodic migraine, ∼75% reported a history of aura at screening; of patients with chronic migraine, ∼35% reported a history of aura. Changes in monthly migraine days over Weeks 1-12 were -4.0 (100 mg) and -4.2 (300 mg) with eptinezumab versus -3.1 with placebo in patients with episodic migraine with aura, and were -7.1 (100 mg) and -7.6 (300 mg) with eptinezumab versus -6.0 with placebo in patients with chronic migraine with aura. Treatment-emergent adverse events were reported by 56.0% (100 mg), 57.4% (300 mg), and 55.4% (placebo) of patients.

CONCLUSIONS: The preventive migraine efficacy of eptinezumab in patients in the PROMISE studies who self-reported aura was comparable to the overall study populations, demonstrating a similarly favorable safety and tolerability profile.Trial registration: ClinicalTrials.gov Identifiers: NCT02559895 and NCT02974153.

Original languageEnglish
JournalCephalalgia : an international journal of headache
Volume42
Issue number8
Pages (from-to)696-704
Number of pages9
ISSN0333-1024
DOIs
Publication statusPublished - Jul 2022

    Research areas

  • efficacy, Eptinezumab, migraine prevention, migraine with aura

ID: 75687480